Cureus | KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer | Article
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors | PNAS
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
Frontiers | Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
Targeting Mutant KRAS for Immunogenic Cell Death Induction: Trends in Pharmacological Sciences
KRAS - Wikipedia
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
Targeting mutated GTPase KRAS in tumor therapies - ScienceDirect
Frontiers | The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant | Molecular Pharmaceutics
Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein | PNAS
Targeting KRAS in Lung Cancer: The Past, Present, and Future - ILCN.org (ILCN/WCLC)
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Sotorasib for Lung Cancers with KRAS p.G12C Mutation | NEJM
JCM | Free Full-Text | KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncology
KRAS Biomarker | Colorectal Cancer Alliance
Targeted Therapy for 'Undruggable' Lung Cancer Stems from Decades of UCSF Research | UC San Francisco
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance: Trends in Cancer
KRAS inhibitors, approved | Nature Cancer
